Physicochemical Properties
| Molecular Formula | C21H16CLN3OS2 |
| Molecular Weight | 425.95 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 24.34 μM (EGFR Kinase) |
| ln Vitro | EGFR kinase inhibitor 5 (0-80 μM, 72 h) inhibits the migration of cancer cells A549 and the activity of cancer cells A549, MCF7 and HCT116, with IC50 values of 21.06, 29.25 and >60 μM, respectively[1]. Cell Migration Assay [1] Cell Line: A549 Concentration: 0-30 μM Incubation Time: 24 h Result: Inhibited cell migration. |
| ln Vivo | EGFR kinase inhibitor 6 (13.37 mg/kg, oral, 15 days) exhibited anti-inflammatory activity in the carrageenan-induced rat paw edema model and was less likely to induce ulceration and lipid peroxidation [1]. |
| Animal Protocol |
Animal/Disease Models: carrageenan-induced hind paw edema in Wistar rats model[1] Doses: 0.0314 mmol/kg Route of Administration: p.o., 15 days Experimental Results: Inhibited 81.34% paw edema. |
| References |
[1]. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents. Sci Rep. 2024 Apr 11;14(1):8457. |
Solubility Data
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3477 mL | 11.7385 mL | 23.4769 mL | |
| 5 mM | 0.4695 mL | 2.3477 mL | 4.6954 mL | |
| 10 mM | 0.2348 mL | 1.1738 mL | 2.3477 mL |